Novostia, a project based on heart valve technology, have announced it will be awarded €2.5m from the European Union’s highly competitive EIC Accelerator.
The EIC Accelerator, as part of the European Innovation Council (EIC) pilot, supports innovative companies with funding opportunities and support services in order to help them to create and market innovative products that could potentially stimulate economic growth.
Novostia’s main goal is to improve the quality of life of those suffering from heart valve disease by providing them with a unique, durable, anticoagulant-free, silent heart valve prosthesis.
“This grant, together with our recent financing round of CHF 6.5 million, will accelerate the development of our technology toward the first in human studies.
“We appreciate the trust and support from the European Union, our investors, and partners and look forward to bringing this long-awaited innovation to patients and physicians”, said Geoffroy Lapeyre, Novostia CEO.
“I have been impressed by the Triflo valve and look forward to starting first-in-human clinical trials. This valve has the potential to benefit thousands of patients, especially young people.” Professor Thierry Carrel, MD, University Hospital of Bern, Switzerland.
According to Novostia: “Novostia is a privately held medical device company incorporated in 2017 in Neuchâtel, Switzerland, developing an innovative artificial heart valve, especially for young patients.
“With the support of world leading surgeons, Novostia endeavors to improve the quality of life of millions of patients worldwide suffering from aortic and mitral valve disease, while reducing overall healthcare costs.
“Novostia’s patented technology results from years of R&D with world leaders in fluid mechanics, advanced biomaterials, high-precision Swiss manufacturing and prominent academic laboratories.”
The Triflo valve was created after years of research in collaboration with world leaders in aeronautics, medicine and science. The project has successfully implanted 100 long-term (up 1.5 years) anticoagulant implants without the presence of obstructive thrombosis.
